https://accure.health/new-targets-and-therapeutics-for-neuroprotection-remyelination-and-repair-in-multiple-sclerosis/ 2020-05-28T10:08:43+00:00 monthly 0.2 https://accure.health/accure-therapeutics-launches-with-e7-6m-series-a-round/ 2020-06-05T11:58:38+00:00 monthly 0.2 https://accure.health/accure-therapeutics-strengthens-scientific-advisory-board-by-appointing-top-class-scientists/ 2021-01-12T08:17:51+00:00 monthly 0.2 https://accure.health/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/ 2021-01-26T11:21:42+00:00 monthly 0.2 https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/ 2021-03-01T19:17:10+00:00 monthly 0.2 https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/ 2021-03-01T19:41:39+00:00 monthly 0.2 https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/ 2021-06-25T08:41:03+00:00 monthly 0.2 https://accure.health/accure-therapeutics-presented-at-ectrims-four-communications-reporting-the-progress-of-act-01-neuroprotective-therapy-for-multiple-sclerosis/ 2021-11-18T13:31:17+00:00 monthly 0.2 https://accure.health/24-nov-conferencia-online-la-esclerosis-multiple-en-los-proximos-15-anos/ 2021-11-18T13:22:56+00:00 monthly 0.2 https://accure.health/oculis-strengthens-leading-ophthalmology-pipeline-by-in-licensing-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/ 2022-09-08T16:09:02+00:00 monthly 0.2 https://accure.health/accure-therapeutics-presented-at-ean-the-improvement-of-neurodegeneration-with-act-02-in-a-preclinical-study-of-parkinsons-disease/ 2022-06-30T09:41:16+00:00 monthly 0.2 https://accure.health/lagencia-per-a-la-competitivitat-de-lempresa-accio-en-data-1-de-marc-de-2018-ha-atorgat-a-iproteos-accure-therapeutics-la-concessio-duna-subvencio-per-les-seves-aportaci/ 2022-06-29T20:28:25+00:00 monthly 0.2 https://accure.health/the-gelatinase-inhibitor-act-03-reduces-gliosis-in-the-rapid-kindling-rat-model-of-epilepsy-and-attenuates-inflammation-and-loss-of-barrier-integrity-in-vitro/ 2022-11-15T10:03:06+00:00 monthly 0.2 https://accure.health/accure-therapeutics-appoints-dr-philippe-monteyne-as-chairman-of-the-board-of-directors/ 2024-02-15T18:48:48+00:00 monthly 0.2 https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/ 2024-05-06T11:57:40+00:00 monthly 0.2 https://accure.health/accure-therapeutics-partner-oculis-reached-positive-phase-2-results-for-lead-neuroprotective-therapy/ 2025-01-10T12:45:30+00:00 monthly 0.2 https://accure.health/accure-therapeutics-awarded-a-total-of-1-6m-in-grants-from-the-michael-j-fox-foundation-and-fonds-national-de-recherche-de-luxembourg-to-bring-first-in-class-drug-for-parkinsons-disease-t/ 2025-04-07T10:26:35+00:00 monthly 0.2